Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.
Status:
Not yet recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
This trial is a multicenter, 4-cohort, prospective, Phase II trial conducted in patients with
untreated resectable MSI/dMMR carcinomas or EBV+ gastric cancer and aiming to evaluate the
safety and the efficacy of ICI (immune checkpoint inhibitor) as neoadjuvant treatment in
these patients.
We hypothesize that immune checkpoint inhibitors (ICPi) will benefit to MSI/dMMR tumors from
the early stages, whatever their anatomical origin. We assume that this neoadjuvant treatment
would improve the response rate, providing even high rate of pathological complete responses
and prolong patients survival.
We anticipated endometrial, colorectal and gastric cancers to be the most frequent recruited
and constructed our statistical hypothesis with results in those 3 cancers. However patients
with other localized MSI/dMMR tumors could be included.